HIV, the virus that causes AIDS, attacks the body’s immune system. This assault leaves people vulnerable to developing other infections and diseases. Although treatments can control HIV infection, HIV persists in the body for a lifetime.
Exhaust from cars and trucks is a significant source of outdoor air pollution. When we breathe in high levels of the particles present in exhaust, these particles can irritate the lungs and cause breathing disorders.
A study in Neurology suggests that analyzing levels of the protein p75ECD in urine samples from people with amyotrophic lateral sclerosis (ALS) may help monitor disease progression as well as determine the effectiveness of therapies. The study was supported by National Institute of Neurological Disorders and Stroke (NINDS) and National Center for Advancing Translational Sciences (NCATS), both part of the National Institutes of Health.
A blood test for a protein called high-sensitivity troponin T, which is released into the bloodstream when injury to the heart occurs, can identify patients with heart damage after non-cardiac surgery whose lives could potentially be saved with timely treatment, according to research presented at the American College of Cardiology's 66th Annual Scientific Session.
Trovagene, Inc., a precision medicine biotechnology company, and Nerviano Medical Sciences, S.r.l., a leading oncology discovery organization, today announced that they have signed a license agreement that grants Trovagene exclusive global development and commercialization rights to NMS-1286937, which Trovagene refers to as PCM-075.
In the first randomized, double-blinded trial of an online behavioral intervention for high blood pressure, participants in web-based lifestyle counseling reduced their systolic blood pressure (the higher number in a blood-pressure reading) by 10 mmHg, compared with a 6 mmHg reduction for those taking part in a web-based control intervention, a statistically significant difference.
In a clinical program that was terminated early, the experimental PCSK9 inhibitor bococizumab, when given on top of effective statin therapy, had widely varying effects on LDL cholesterol levels and had no benefit on cardiovascular events among those with LDL lower than 100 mg/dL.
MSD, nota con il nome di Merck negli Stati Uniti e in Canada, ha annunciato che l’ente regolatorio americano (Food and Drug Administration, FDA) ha approvato pembrolizumab, terapia anti-PD-1 (programmed death receptor-1), per il trattamento di pazienti adulti e pediatrici con linfoma di Hodgkin classico (cHL) refrattario o recidivati dopo tre o più linee di terapia, indipendentemente da precedente trapianto autologo o uso di brentuximab vedotin.
Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or "bad" cholesterol, also significantly lowers the risk of cardiovascular events in patients with existing heart or vascular disease already on statin therapy, according to research presented at the American College of Cardiology's 66th Annual Scientific Session.